1| Transfer heparinized venous blood of patient to plastic50-ml tubes and dilute with an equal volume of PH buffer.
When sodium citrate has been used as anticoagulant, add an equal volume of PT buffer. When PBMCs are isolated from a buffy coat, transfer the buffy coat to a 250-ml flask and add PT buffer to a final volume of 150 ml.
2| Gently load 25 ml of diluted blood on top of 12.5 ml of a Ficoll-Isopaque solution with a density of 1.077 g ml1 in a 50-ml tube.
3| Centrifuge at 760g for 20 min at room temperature (21 ± 5 1C). Slow acceleration and do not use brake.
4| Collect the cell band on top of the Ficoll layer with a Pasteur pipette and transfer it to a new 50-ml tube (maximum of 2 cell bands per tube) and add PH or PT buffer till a final volume of 50 ml. Centrifuge at 425g for 15 min at room temperature.
5| Wash the harvested cells twice in a total volume of 50 ml of PH or PT buffer and centrifuge at 425g for 10 min at room temperature.It is important to completely resuspend the cell pellet for each wash to ensure thrombocyte removal (see also below).
6| Resuspend the cells in IF medium and count the cells using an automated cell counter.
CAUTION Working with primary cells from blood donors and HIV-1 infected patients may result in the frequent introductionof mycoplasma. Precautions should be taken to prevent infection of other cells or cell lines. It is recommended to add ciprofloxacin to the cultures, to inhibit replication of mycoplasma.
CRITICAL STEP The presence of thrombocytes in the PBMCs cultures will have a negative effect on isolation of HIV-1. When the supernatant is not clear after the second wash (Step 5), large amounts of thrombocytes are still present in the PBMCs, and additional wash steps (repeat Step 5) should be added to remove the thrombocytes.
PAUSE POINT PBMCs can now be either cryopreserved in IMDM containing 10% (vol/vol) FCS and 10% (vol/vol) DMSO or directly used. Cryopreserved PBMCs can be stored in liquid nitrogen for more than 10 years.
Determination of a 32 bp deletion in the CCR5 gene of PBMCs donors
7| Isolate genomic DNA from 1 106 PBMCs or 200 ml of blood using the Qiagen blood kit or equivalent alternative,according to the manufacturer’s instructions.
8| Prepare the PCR mix as follows using primers CCR5-sense (position 427 to 450 in CCR5 (NM_001105536): 5¢-GATAGGTACCTGGCTGTCGTCCAT-3¢) and CCR5-antisense (position 665 to 644 in CCR5 (NM_001105536): 5¢-ACCAGCCCCAAGATGACTATCT-3¢)
flanking the described 32-nt deletion in the CCR5 gene.
Reagent Amount (ll)
PCR reaction buffer (10) 5
dNTP (5 mM) 2
MgCl (50 mM) 2.6
Primer CCR5-sense (100 ng ml1) 1
Primer CCR5-antisense (100 ng ml1) 1
Taq DNA polymerase 0.2
H2O 33.2
Total volume 45
9| Add 5 ml (10–100 ng) of genomic DNA to the reaction.
10| Amplify the PCR products under the following conditions in a thermocycler:
Step Temperature (1C) Time Number of cycles
1 95 5 min 1
2 95 5 s 35
55 10 s
72 1 min
3 72 2 min 1
4 4 N 1
蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......
2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......
2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......
研究闡明了SETD2在調控骨髓增生異常綜合征(MDS)向急性髓系白血病(AML)轉化過程中的作用機制,為MDS臨床治療提供了理論基礎和潛在靶標。MDS是最常見的髓系惡性腫瘤之一,是起源于造血干細胞的一......
為什么有些癌癥治療之后仍會復發?有時候,癌癥的相關治療可以有效地將癌細胞消除到無法檢測的水平,但是,如果停止治療,癌癥可能會復發。例如,在用酪氨酸激酶抑制劑藥物治療慢性粒細胞白血病患者是就會出現停藥后......
化療已使最常見的兒童期癌癥---急性淋巴細胞白血病(ALL)---成為最可治愈的癌癥之一,但是科學家們有證據表明這種治療也可能使某些患者復發。在一項新的研究中,來自中國和美國的研究人員報道由治療引起的......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......
2018年12月6日,來自圣迭戈的消息——Illumina公司(納斯達克股票代碼:ILMN)今天宣布推出新型高密度基因分型芯片Infinium?GlobalDiversityArray。這款芯片設計源......
在一項新的研究中,來自美國俄亥俄州大學的DaniloPerrotti和同事證實一種叫做FTY720的藥物能夠抑制由癌癥蛋白BCR-ABL導致的白血病小鼠模型的病情。由于這種藥物還能夠誘導從白血病患者獲......